EMMA (Emmaus Life Sciences) Cyclically Adjusted PB Ratio: (As of Jul. 09, 2026)


What is Emmaus Life Sciences Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Emmaus Life Sciences  (OTCPK:EMMA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Emmaus Life Sciences Cyclically Adjusted PB Ratio Related Terms


Emmaus Life Sciences Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences Cyclically Adjusted PB Ratio Chart

Emmaus Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Emmaus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

EMMA vs PTIX, BZYR, RMTG: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Emmaus Life Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emmaus Life Sciences Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Cyclically Adjusted PB Ratio falls into.



Emmaus Life Sciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Emmaus Life Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Emmaus Life Sciences's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.968/330.2130*330.2130
=-0.968

Current CPI (Mar. 2026) = 330.2130.

Emmaus Life Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201606 -83.011 241.018 -113.731
201609 -3.287 241.428 -4.496
201612 2.040 241.432 2.790
201703 1.252 243.801 1.696
201706 -2.253 244.955 -3.037
201709 6.342 246.819 8.485
201712 2.930 246.524 3.925
201803 2.525 249.554 3.341
201806 2.983 251.989 3.909
201809 3.255 252.439 4.258
201812 1.720 251.233 2.261
201903 1.359 254.202 1.765
201906 1.795 256.143 2.314
201909 -0.368 256.759 -0.473
201912 -0.228 256.974 -0.293
202003 -0.097 258.115 -0.124
202006 -0.286 257.797 -0.366
202009 -0.130 260.280 -0.165
202012 -0.105 260.474 -0.133
202103 -0.257 264.877 -0.320
202106 -0.190 271.696 -0.231
202109 -0.306 274.310 -0.368
202112 -0.435 278.802 -0.515
202203 -0.452 287.504 -0.519
202206 -0.699 296.311 -0.779
202209 -0.758 296.808 -0.843
202212 -0.688 296.797 -0.765
202303 -0.706 301.836 -0.772
202306 -0.653 305.109 -0.707
202309 -0.677 307.789 -0.726
202312 -0.772 306.746 -0.831
202403 -0.867 312.332 -0.917
202406 -0.893 314.175 -0.939
202409 -0.842 315.301 -0.882
202412 -0.884 315.605 -0.925
202503 -0.918 319.799 -0.948
202506 -0.872 322.561 -0.893
202509 -0.931 324.800 -0.947
202512 -0.906 324.054 -0.923
202603 -0.968 330.213 -0.968

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.